- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05051761
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (AA)
March 4, 2024 updated by: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50% or greater scalp hair loss.
The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo).
It is double-blinded, meaning that the Sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
420
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Peking University People's Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210042
- Hospital for Skin Diseases, Chinese Academy of Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- participants voluntarily sign the informed consent form (ICF);
- Age ≥ 18 years and <65 years, either male or female;
- Clinical presentation compatible with alopecia areata with a current episode lasting not exceeding ≤8 years.
- At least 50% scalp hair loss.
- Willing to comply with the study visits and requirements of the study protocol.
Exclusion Criteria:
- participants has taken a JAK inhibitor prior to randomization;
- participants who are unsuitable to the trial, as identified by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Jaktinib 50mg BID
Participants received Jaktinib 50mg tablets, orally, twice daily (BID) for up to 24 weeks.
|
Administered orally.
|
Experimental: Jaktinib 75mg BID
Participants received Jaktinib 75mg tablets, orally, twice daily (BID) for up to 24 weeks.
|
Administered orally.
|
Placebo Comparator: placebo
Participants received Jaktinib matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.
|
Administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 at Week 24
Time Frame: Week 24
|
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving 50% Improvement of SALT (SALT50)
Time Frame: Week 24
|
Percentage of participants achieving SALT50
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Jason Wu, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 4, 2021
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
September 11, 2021
First Submitted That Met QC Criteria
September 20, 2021
First Posted (Actual)
September 21, 2021
Study Record Updates
Last Update Posted (Actual)
March 6, 2024
Last Update Submitted That Met QC Criteria
March 4, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZGJAK018
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia Areata
-
Eli Lilly and CompanyRecruitingSkin Diseases | Pathological Conditions, Anatomical | Alopecia | Hypotrichosis | Hair Diseases | Areata AlopeciaUnited States, Taiwan, Japan, Spain, Korea, Republic of, Germany, France, Mexico, Canada, Poland, Australia, Hungary, Argentina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingAlopecia Areata(AA)China
-
University Hospital, RouenCompletedALOPECIA AREATAFrance
-
Services Institute of Medical Sciences, PakistanCompletedExtensive Alopecia AreataPakistan
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Inmagene LLCRecruitingAlopecia Areata (AA)United States, Canada
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
EquilliumWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
-
Lindsey BordoneWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
Clinical Trials on Jaktinib
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdNot yet recruitingAcute Graft-Versus-Host DiseaseChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedHepatic Insufficiency | Healthy SubjectsChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedPrimary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis(Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)China
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingAlopecia Areata(AA)China
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedAnkylosing SpondylitisChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingAnkylosing SpondylitisChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted